HC Wainwright Lowers Earnings Estimates for Kodiak Sciences
HC Wainwright has revised its Q3 2026 earnings per share (EPS) estimates for Kodiak Sciences, lowering it to a loss of $0.89 from $0.80, while maintaining a "Buy" rating and a $58 price target. This adjustment follows Kodiak Sciences reporting a Q2 loss of $1.05 per share, which missed the consensus estimate. Despite the lowered estimates, the overall analyst consensus for Kodiak Sciences remains a "Moderate Buy" with an average target price of $48.14.
GSA Capital Partners LLP Takes $1.07 Million Position in Kodiak Sciences Inc. $KOD
GSA Capital Partners LLP acquired a new position in Kodiak Sciences Inc. (NASDAQ:KOD) during the second quarter, purchasing 27,525 shares valued at approximately $1.07 million. Institutional investors and hedge funds now own 89.06% of Kodiak Sciences stock. Analyst sentiment for the company is a "Moderate Buy" with an average price target of $48.14, despite missing recent quarterly earnings estimates.
H.C. Wainwright Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $58
H.C. Wainwright has reiterated its Buy rating on Kodiak Sciences (KOD.US) and maintained a target price of $58. This indicates the firm's continued confidence in the company's prospects. Investors may find this analyst rating useful in their evaluation of Kodiak Sciences.
KOD Reiterates by HC Wainwright & Co. -- Price Target Maintained at $58
HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating for Kodiak Sciences (KOD), maintaining a price target of $58.00 despite the company's current stock price of $41.37. The company, which operates in the biotechnology sector and focuses on retinal medicines, has a low GF Score™ of 27/100, indicating areas for improvement in profitability and growth. Insider activity shows $1.0 million in selling over the last three months with no buying, and guru ownership is mixed.
HC Wainwright Reaffirms "Buy" Rating for Kodiak Sciences (NASDAQ:KOD)
HC Wainwright has reiterated its "Buy" rating for Kodiak Sciences (NASDAQ:KOD) and set a $58 price target, indicating a potential upside of approximately 40%. Despite a quarterly loss of $1.05 per share, below analyst estimates, the company maintains a "Moderate Buy" consensus rating from analysts. Institutional investors hold a significant 89.06% stake in the clinical-stage biopharmaceutical company, which focuses on developing therapies for retinal diseases.
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy
H.C. Wainwright has reiterated a buy rating and a $58.00 price target for Kodiak Sciences Inc. (NASDAQ:KOD), highlighting the stock's significant surge over the past year. The firm anticipates key topline data from two Phase 3 trials in September and December 2026, which are considered near-term catalysts for the company's retinal therapeutics pipeline. Despite these potential advancements, Kodiak Sciences reported a wider-than-expected net loss in its Q2 financial results, primarily due to increased research and development expenses.
H.C. Wainwright reiterates Kodiak Sciences stock rating at buy
H.C. Wainwright has reiterated a buy rating and a $58.00 price target for Kodiak Sciences Inc. (NASDAQ: KOD), whose stock has seen a 291% surge over the past year. The firm highlighted two near-term catalysts in the company's retinal therapeutics pipeline: the Phase 3 DAYBREAK trial's primary endpoint topline in September 2026 and the Phase 3 PEAK pivotal analysis-1 topline in December 2026. Despite a wider net loss reported in the second quarter, these advancements underscore the company's ongoing efforts in its late-stage clinical programs.
California State Teachers Retirement System Has $1.12 Million Stock Holdings in Kodiak Sciences Inc. $KOD
The California State Teachers Retirement System significantly increased its stake in Kodiak Sciences Inc. (NASDAQ:KOD) by 1,358.9% in the first quarter, now holding 29,396 shares valued at $1.12 million. Other institutional investors also adjusted their positions, with 89.06% of the stock owned by institutional investors and hedge funds. Despite missing analyst earnings expectations, Kodiak Sciences maintains a "Moderate Buy" consensus rating with a price target of $48.14.
Wall Street Zen Downgrades Kodiak Sciences (NASDAQ:KOD) to Sell
Wall Street Zen downgraded Kodiak Sciences (NASDAQ:KOD) from "hold" to "sell" on Saturday, despite the broader analyst consensus being a "Moderate Buy." The company's shares opened near their 52-week high at $41.35, but Kodiak Sciences reported a larger-than-expected quarterly loss of $1.05 per share. Institutional investors hold a significant portion of the company's stock, with major investments from firms like BlackRock Inc. and Baker Bros. Advisors.
UBS Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $80
UBS has reiterated its Buy rating for Kodiak Sciences (KOD.US) and maintained its target price at $80. This indicates a continued positive outlook from the financial institution regarding the company's stock performance.
Kodiak Sciences misses Q2 estimates, shares fall 5% By Investing.com
Kodiak Sciences Inc. reported a wider Q2 net loss of -$1.05 per share, missing analyst estimates of -$0.98 per share, leading to a 5.23% drop in shares. The biotechnology company's research and development expenses increased due to heightened clinical activities for its retinal disease programs. Despite the Q2 miss, Kodiak expects its cash reserves to support operations into 2027 and anticipates key Phase 3 clinical trial results later this year.
Kodiak Sciences (NASDAQ:KOD) Shares Gap Down - Time to Sell?
Kodiak Sciences (NASDAQ:KOD) shares gapped down before Friday's market open, though they later recovered some ground. The clinical-stage biopharmaceutical company, which focuses on retinal disease treatments, reported a quarterly loss that missed analyst estimates. Despite the earnings miss, analyst sentiment is generally positive, with a "Moderate Buy" consensus rating and an average price target above the current trading price.
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus
Kodiak Sciences reported a wider-than-expected Q2 2026 loss of $1.05 per share, surpassing the Zacks Consensus Estimate of a 97-cent loss. Despite increased R&D expenses for pipeline development, the company's cash position is expected to sustain operations into 2027. Kodiak is accelerating regulatory submissions for its lead candidate Zenkuda and advancing other investigational therapies, KSI-501 and KSI-101, for various retinal diseases.
Kodiak Sciences misses Q2 estimates, shares fall 5%
Kodiak Sciences Inc. (NASDAQ:KOD) reported a wider net loss of -$1.05 per share for Q2, missing analyst estimates of -$0.98 per share, leading to a 5.23% drop in shares after hours. The biotechnology company's R&D expenses increased due to clinical activities for its retinal disease programs, but it expects its current cash to fund operations into 2027. The company is anticipating key Phase 3 clinical trial results in September and December 2026.
Kodiak's Q2 Loss Wider Than Expected, Pipeline Development in Focus
Kodiak Sciences (KOD) reported a wider-than-expected Q2 2026 loss of $1.05 per share, primarily due to increased R&D expenses for ongoing clinical studies. Despite this, the company's shares have risen significantly year-to-date, driven by advancements in its pipeline, including the accelerated regulatory submission for its lead candidate, Zenkuda, and progress in studies for KSI-501 and KSI-101 for retinal vascular diseases. Kodiak expects its cash position to fund operations into 2027.
Kodiak Sciences (NASDAQ:KOD) Releases Earnings Results, Misses Estimates By $0.09 EPS
Kodiak Sciences (NASDAQ:KOD) reported a quarterly loss of $1.05 per share, missing analysts' consensus estimates by $0.09. Following the earnings release, the stock fell 7.9% to $39.98, despite a "Moderate Buy" consensus rating and an average price target of $48.14 from analysts. Institutional investors own a significant portion of the company's stock, with several firms adjusting their positions recently.
Kodiak Sciences misses Q2 estimates, shares fall 5%
Kodiak Sciences Inc. reported a wider net loss of -$1.05 per share in Q2, missing analyst estimates of -$0.98 per share, causing shares to drop over 5% in after-hours trading. The company's R&D expenses increased due to late-stage clinical programs for retinal diseases, though it expects current cash to fund operations into 2027 with several Phase 3 readouts anticipated by year-end.
Kodiak Sciences posts Q2 2026 net loss of $65.6M, cash $125.9M; DAYBREAK, PEAK readouts due Sept–Dec 2026
Kodiak Sciences reported a Q2 2026 net loss of $65.6 million and ended the quarter with $125.9 million in cash, expected to fund operations into 2027. The company reiterated upcoming Phase 3 topline readouts for DAYBREAK in September 2026 and PEAK Pivotal Analysis 1 in December 2026. Research and development expenses increased to $56.1 million due to higher Phase 3 clinical and manufacturing activities.
Kodiak Sciences Enrols First Patients in Phase III ALTO Trial of KSI-501 for Diabetic Macular Edema
Kodiak Sciences has enrolled the first patients in its global Phase 3 ALTO trial for KSI-501, a bispecific therapy targeting diabetic macular edema (DME). The trial aims to demonstrate the superiority of KSI-501, which inhibits both IL-6 and VEGF pathways, over existing anti-VEGF treatments by providing deeper, more sustained disease control and potentially improving vision and fluid management. This marks a significant step in advancing multifunctional retinal medicines beyond single-pathway inhibition for DME patients.
Kodiak Sciences enrolls first patients in phase 3 DME trial
Kodiak Sciences Inc. has begun enrolling patients in its global Phase 3 ALTO trial for KSI-501, a bispecific therapy for diabetic macular edema (DME). This trial compares KSI-501 against aflibercept and is the second registrational Phase 3 study for the drug. KSI-501 is designed to inhibit IL-6 and VEGF pathways and follows the DAYBREAK study in wet AMD, with topline data for DAYBREAK expected in September 2026.
KOD Begins Late-Stage Study of KSI-501 in Diabetic Macular Edema
Kodiak Sciences (KOD) has initiated a global late-stage ALTO study to evaluate KSI-501 in patients with diabetic macular edema (DME). KSI-501 is a bispecific therapy targeting IL-6 and VEGF, aiming for better visual improvements, retinal fluid control, and treatment durability. The study will compare KSI-501 against Eylea, with results anticipated to show deeper and more sustained disease control for DME patients, especially those not fully responsive to anti-VEGF monotherapy.
Return on assets % of Kodiak Sciences, Inc. – HAM:K27
This article displays the "Return on assets %" for Kodiak Sciences, Inc. (HAM:K27) on TradingView. It indicates that the market is closed with no trades recorded. The content primarily focuses on financial data for Kodiak Sciences, Inc.
Kodiak Sciences enrolls first patients in phase 3 DME trial By Investing.com
Kodiak Sciences Inc. has begun enrolling patients in its global Phase 3 ALTO trial for KSI-501, a bispecific therapy for diabetic macular edema (DME). This trial will compare KSI-501 against aflibercept and is the second registrational Phase 3 study for KSI-501, following the DAYBREAK trial for wet AMD. The company expects topline data from the DAYBREAK study in September 2026.
Kodiak Sciences starts Phase 3 trial for KSI-501 to treat diabetic macular edema, aiming to outperform aflibercept.
Kodiak Sciences has initiated the global Phase 3 ALTO trial for KSI-501, a bispecific therapy for diabetic macular edema (DME). The trial seeks to demonstrate KSI-501's superiority over aflibercept by offering improved vision and longer-lasting effects with fewer injections. This development follows positive Phase 2 results and could lead to a more effective treatment for DME.
Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
Kodiak Sciences Inc. has announced the enrollment of the first patients in its global Phase 3 ALTO trial for KSI-501, a bispecific therapy targeting diabetic macular edema (DME). The trial aims to demonstrate KSI-501's superiority over aflibercept by inhibiting both IL-6-mediated inflammation and VEGF-mediated vascular issues, potentially offering deeper and more sustained disease control with less frequent dosing. This study builds on previous research suggesting dual inhibition could lead to improved visual and anatomical outcomes for DME patients.
Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema
Kodiak Sciences (Nasdaq: KOD) has initiated its global Phase 3 ALTO trial for KSI-501 in diabetic macular edema (DME), enrolling the first patients. This study aims to demonstrate the superiority of KSI-501, a bispecific therapy targeting both IL-6 and VEGF pathways, over aflibercept monotherapy. The trial will evaluate two dosing regimens for KSI-501, including one with individualized intervals of up to six months, with primary efficacy data expected between Weeks 48-52.
Debt to equity ratio of Kodiak Sciences, Inc. – HAM:K27
This article displays the debt to equity ratio for Kodiak Sciences, Inc. (HAM:K27), sourced from TradingView. It provides financial data for the company, indicating the period, value, and change in its debt to equity ratio. The page is primarily a financial data display rather than an analytical article.
Kodiak Sciences (KOD) Is Up 9.1% After Advancing KSI-101 Phase 3 PEAK Trial Enrollment – Has The Bull Case Changed?
Kodiak Sciences (KOD) has completed enrollment of the first 300-patient cohort in its Phase 3 PEAK trial for KSI-101, a bispecific IL-6/VEGF therapy for macular edema. This milestone provides a clearer timeline for pivotal readouts in late 2026 and mid-2027, reinforcing the existing risk and catalyst profile for the company, which is currently loss-making with limited cash. Despite a recent stock price rise, fair value estimates vary widely, highlighting differing views on the company's potential.
LifeSci Capital Maintains Kodiak Sciences(KOD.US) With Buy Rating, Maintains Target Price $65
LifeSci Capital has reiterated its Buy rating for Kodiak Sciences (KOD.US) and maintained its target price at $65. This indicates continued confidence from the firm in the company's financial prospects and stock performance.
The Manufacturers Life Insurance Company Acquires 29,121 Shares of Kodiak Sciences Inc. $KOD
The Manufacturers Life Insurance Company increased its stake in Kodiak Sciences Inc. (NASDAQ:KOD) by 31.8% during the first quarter, adding 29,121 shares to own a total of 120,629 shares valued at $4.6 million. This move is part of a broader trend of institutional investors, who collectively own 89.06% of KOD, modifying their holdings. Analysts generally hold a "Moderate Buy" consensus rating with an average price target of $48.14, and the company is developing therapies for retinal diseases with its lead candidate, KSI-301.
Kodiak Sciences Inc (KOD) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Kodiak Sciences Inc (KOD), highlighting analyst ratings, target prices, and future EPS and revenue growth estimates. Based on 6 analysts, the stock has a "Buy" rating with a target price of USD 14.00, suggesting a potential upside of over 50%. The report also includes past and future EPS expectations.
Kodiak completes enrollment in first KSI-101 trial cohort By Investing.com
Kodiak Sciences Inc. (NASDAQ:KOD) has successfully completed enrollment of 300 patients in the first cohort of its PEAK trial for KSI-101, which targets macular edema secondary to inflammation. Topline data from this initial analysis is expected in December 2026. The company also plans to complete enrollment for a second cohort of 600 subjects across its PEAK and PINNACLE studies by Q4 2026, with data anticipated in Q2 2027.
Kodiak's Trial Tests KSI-101 for Macular Edema Secondary to Inflammation
Kodiak Sciences (NASDAQ: KOD) has completed enrollment for the first 300-patient pivotal cohort in its Phase 3 PEAK trial for KSI-101, targeting macular edema secondary to inflammation (MESI). Topline clinical data from this cohort are expected in December 2026, with a second cohort of approximately 600 subjects across PEAK and PINNACLE studies anticipated to complete enrollment by Q4 2026 and yield data by Q2 2027. KSI-101 aims to reduce inflammation, dry the retina, and improve vision in MESI patients, a condition distinct from other common causes of retinal edema.
Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026
Kodiak Sciences Inc. has completed enrollment of the first 300-patient cohort in its Phase 3 PEAK trial for KSI-101, targeting macular edema secondary to inflammation (MESI). The company reaffirmed that topline data from this pivotal analysis is expected to be released in December 2026. This milestone is a crucial step towards potentially introducing KSI-101 as a new treatment option for MESI, a condition currently lacking intravitreal biologic therapies.
J.P. Morgan Maintains Kodiak Sciences(KOD.US) With Buy Rating, Raises Target Price to $66
J.P. Morgan has reiterated its Buy rating for Kodiak Sciences (KOD.US) and increased the target price to $66. This update from the financial firm indicates a continued positive outlook on the company's stock.
KOD Maintained by JP Morgan -- Price Target Raised to $66.00
JP Morgan maintained an "Overweight" rating for Kodiak Sciences (KOD) and raised its price target from $56.00 to $66.00, indicating positive analyst sentiment despite the company's low GF Score™ of 27/100 and insider selling. Kodiak Sciences, with a market cap of $2.61 billion, is developing investigational medicines for retinal diseases, but struggles with profitability. While analysts are optimistic about its pipeline, investors should consider its unprofitability and mixed insider/guru activity.
KODIAK SCIENCES INC : JP MORGAN RAISES TARGET PRICE TO $66 FROM $56
JP Morgan has increased its target price for Kodiak Sciences Inc. (KOD.O) shares to $66 from $56. This update was reported by Reuters on August 3, 2026. The article reiterates this price target adjustment.
KOD|Kodiak Sciences Inc|Price:41.580|Chg%:-0.920
This article provides a financial overview of Kodiak Sciences Inc. (KOD), including its stock price, market cap, and a detailed breakdown of its income statement, balance sheet, and cash flow statement for various quarters and fiscal years. It also highlights key financial indicators like EPS, net profit, debt to assets ratio, and upcoming earnings information. The data presented aims to offer investors a comprehensive financial analysis of the company.
Kodiak Sciences Inc Revenue Breakdown – NASDAQ:KOD
This page provides an overview of Kodiak Sciences Inc (NASDAQ: KOD) financials on TradingView. It indicates that the market is closed with no trades and offers various financial data categories such as statements, statistics, dividends, earnings, and segments. The content also details how market and reference data are provided by ICE Data Services and FactSet, respectively.
Kodiak Sciences, Inc. Revenue Breakdown – SWB:K27
This article provides a revenue breakdown for Kodiak Sciences, Inc. (SWB:K27) on TradingView. It appears to be a financial data page rather than a traditional article, focusing on company financials, stock exchange information, and various tools available on the TradingView platform for analyzing the company's performance.
Kodiak Sciences Inc (KOD) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Kodiak Sciences Inc (KOD), detailing its support, resistance, and various indicator readings. It presents a summary of technical indicators like MACD, RSI, and StochRSI, along with moving average data (MA5, MA10, MA20, MA50, MA100, MA200). The analysis concludes with a Neutral signal based on moving averages and technical indicators.
Kodiak Sciences, Inc. Revenue Breakdown – BMV:KOD
This article provides financial information for Kodiak Sciences, Inc. (BMV:KOD) listed on the Mexican Stock Exchange through TradingView. It indicates that the market is closed with no trades and gives an overview of available financial statements, statistics, dividends, earnings, and segment data for the company. The content also lists various TradingView products and community features, which are navigational.
Kodiak Sciences Inc Revenue Breakdown – BOATS:KOD
This page provides financial information for Kodiak Sciences Inc. (KOD) on the TradingView platform, specifically focusing on revenue breakdown. It includes sections for an overview, statements, statistics, dividends, earnings, and segment performance. The content is primarily a presentation of available financial data on the TradingView interface rather than an analytical article.
Kodiak Sciences Inc (KOD) Institutional Confidence
This article details the institutional confidence in Kodiak Sciences Inc (KOD) by listing key institutional shareholders and their recent activity. It shows several large investment firms hold significant shares, with notable increases in holdings from State Street Investment Management (US) and T. Rowe Price Associates, Inc. The data indicates growing institutional interest in the company.
Kodiak Sciences Inc (KOD) Cash Flow
This article provides a detailed cash flow statement for Kodiak Sciences Inc (KOD), presenting quarterly and annual figures for operating, investing, and financing activities. It includes key financial metrics such as net income, capital expenditures, and free cash flow, along with definitions and explanations of these various cash flow components to help investors assess the company's financial health.
Kodiak Sciences Inc (KOD) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Kodiak Sciences Inc (KOD), including analyst ratings, price targets, and historic EPS performance. Based on 7 analysts, the stock has a "Buy" consensus, with a target price of $14.00 and an upside potential of 56.02%. The company's previous quarter's EPS was below market expectations, but next quarter's EPS is projected to be USD -0.96.
Kodiak Sciences Inc (KOD) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a detailed risk assessment for Kodiak Sciences Inc (KOD), focusing on its volatility, financial risk, and investment risk. It presents key metrics such as Beta, VaR, Maximum Drawdown, Volatility, Return, Sharpe Ratio, Skewness, and Liquidity. The data covers various timeframes, offering insights into the stock's historical performance and risk characteristics.
Kodiak Sciences Inc (KOD) Valuation: PE, PB & Fair Value Analysis
The TradingKey platform provides an analysis of Kodiak Sciences Inc (KOD), noting its market capitalization and current stock price. However, key valuation metrics like P/E, P/B, and P/CF are not yet disclosed by the company, limiting a comprehensive valuation analysis based on these specific ratios. The article is primarily a stub for the company's valuation analysis on the TradingKey platform.
Kodiak Sciences, Inc. Revenue Breakdown – LS:A2N6P0
This article provides access to the revenue breakdown for Kodiak Sciences, Inc. (LS:A2N6P0) on TradingView. It appears to be a stub or a placeholder page, as it only lists navigation options, market data sources, and copyright information without presenting any actual financial data or analysis for the company. Users can navigate through various sections like financials, documents, news, and more to find information about the company.
Form 4 Kodiak Sciences Inc For: 17 July By Investing.com
This article from Investing.com is a Form 4 filing for Kodiak Sciences Inc., dated July 17. Form 4 filings are used to declare transactions by company insiders, but the article primarily serves as a placeholder, only stating the filing and including general market data with no specific details from Kodiak's filing.
